Latin America Psoriasis Drugs Market Report

To learn more about this report, Download Free Sample Report

Latin America Psoriasis Drugs Market Size

The latin america psoriasis drugs market was valued at USD 0.92 billion in 2025, is estimated to reach USD 0.99 billion in 2025, and is projected to reach USD 1.75 billion by 2034, growing at a CAGR of 7.41% from 2026 to 2034.

The Latin America psoriasis drugs market comprises therapeutic solutions designed to manage chronic immune-mediated skin disorders characterized by erythematous plaques and systemic inflammation across diverse national healthcare systems. This sector encompasses topical corticosteroids, conventional systemics, and advanced biologics tailored to regional epidemiological profiles and regulatory frameworks. According to the Pan American Health Organization, noncommunicable diseases account for 80% of all deaths in the Americas, creating an urgent public health imperative to address chronic inflammatory conditions like psoriasis that contribute significantly to this burden. According to the International Federation of Psoriasis Associations, approximately 2% to 3% of the population in Latin American countries lives with psoriasis, yet significant diagnostic gaps persist due to limited specialist access in rural zones. These statistics illustrate the critical intersection between high disease prevalence and the necessity for accessible pharmacological interventions within the region. The market is currently shaped by evolving reimbursement policies, increasing biosimilar adoption, and growing recognition of psoriasis as a multisystem disease requiring comprehensive long-term management strategies beyond simple symptom control.

MARKET DRIVERS

Rising Recognition of Psoriatic Comorbidities Fuels Systemic Therapy Demand

The escalating clinical recognition of psoriatic comorbidities directly stimulates demand for advanced systemic therapies across Latin American healthcare systems, which is a key factor driving the Latin America psoriasis drugs market expansion. Physicians increasingly understand that psoriasis extends beyond dermatological manifestations to involve cardiovascular, metabolic, and psychological dimensions requiring holistic treatment approaches. According to the Journal of the American Academy of Dermatology, patients with severe psoriasis have a 50% increased risk of developing cardiovascular disease compared to the general population, necessitating aggressive systemic intervention to mitigate long-term health risks. This epidemiological reality drives prescriptions for biologics and oral small molecules that offer superior disease control and potential cardioprotective benefits over traditional topicals. According to the Latin American Society of Rheumatology, up to 30% of psoriasis patients develop psoriatic arthritis, a condition where delayed treatment leads to irreversible joint damage and disability. Early identification of these comorbidities compels healthcare providers to escalate therapy promptly, thereby expanding the addressable market for premium drugs. As medical education improves regarding the systemic nature of psoriasis, more patients receive appropriate referrals to specialists who prescribe advanced agents. This paradigm shift from cosmetic management to comprehensive disease modification fundamentally alters prescribing patterns and sustains growth in the systemic drug segment throughout the region.

Expansion of Public Health Coverage for Chronic Inflammatory Diseases

Broadening public health coverage and government initiatives specifically targeting chronic inflammatory diseases significantly favor market expansion in Latin America. National health systems are progressively incorporating high-cost biologics into essential medicine lists and reimbursement formularies to reduce out-of-pocket burdens for vulnerable populations. According to the World Health Organization, universal health coverage initiatives in countries like Brazil and Colombia have successfully integrated specialty medications for autoimmune disorders, increasing patient access by over 40% in the last decade. This policy-driven accessibility transforms previously unaffordable treatments into viable options for lower-income demographics, directly boosting prescription volumes. According to the Economic Commission for Latin America and the Caribbean, social protection spending on health has risen steadily, reflecting political commitment to managing noncommunicable diseases through subsidized pharmaceutical programs. When governments assume financial responsibility for expensive therapies, manufacturers gain predictable demand streams and can plan supply chains more effectively. The inclusion of newer interleukin inhibitors in public tenders demonstrates how regulatory updates align with global standards of care. Consequently, state-sponsored procurement acts as a powerful volume driver, ensuring that market growth is not solely dependent on private sector purchasing power but is anchored in sustainable public health infrastructure.

MARKET RESTRAINTS

Currency Volatility and Import Dependency Limit Drug Affordability

Severe currency volatility and heavy reliance on imported pharmaceuticals substantially hinder consistent market growth and drug affordability across Latin America. Most advanced psoriasis treatments are manufactured abroad, making their local prices highly sensitive to exchange rate fluctuations against major currencies like the US dollar or euro. According to the Inter-American Development Bank, currency depreciation in several Latin American nations exceeded 20% annually during recent economic downturns, directly inflating the cost of imported biologics and straining both public budgets and private insurance funds. This financial instability forces payers to restrict formulary access or delay the introduction of new therapies to maintain fiscal solvency. According to the United Nations Economic Commission for Latin America and the Caribbean, import tariffs and logistical costs can add up to 30% to the final price of specialty medicines in certain jurisdictions, exacerbating affordability challenges. When national currencies weaken, hospitals and pharmacies often face stockouts as suppliers adjust pricing or halt shipments to avoid losses. Patients consequently experience treatment interruptions that compromise clinical outcomes and reduce overall drug consumption. This macroeconomic fragility creates an unpredictable commercial environment where even clinically necessary drugs become inaccessible due to external financial shocks rather than medical considerations.

Regulatory Heterogeneity and Prolonged Approval Timelines

Fragmented regulatory landscapes and prolonged approval timelines across different Latin American countries act as significant barriers to timely market entry and patient access. Unlike harmonized regions, each nation maintains distinct submission requirements, clinical data expectations, and review processes for new psoriasis drugs. According to the Pan American Health Organization, the median time for marketing authorization of new biologics varies from 12 months in streamlined agencies to over 36 months in others, creating substantial delays in therapeutic availability. This lack of synchronization forces manufacturers to navigate complex bureaucratic pathways individually, increasing operational costs and discouraging launches in smaller markets. According to the Journal of Pharmaceutical Policy and Practice, post-approval surveillance requirements differ widely, leading to additional administrative burdens that delay commercialization even after initial registration. Such regulatory friction prevents patients from benefiting simultaneously with global peers and perpetuates therapeutic inequity within the region. Companies may prioritize larger markets like Brazil or Mexico while deferring entries elsewhere, limiting regional market depth. The uncertainty surrounding approval schedules also complicates forecasting and investment decisions, ultimately restraining the overall dynamism and competitiveness of the Latin America Psoriasis Drugs Market.

MARKET OPPORTUNITIES

Accelerated Biosimilar Adoption through Regulatory Harmonization Efforts

The accelerating adoption of biosimilars facilitated by ongoing regulatory harmonization efforts presents a prominent opportunity for Latin America psoriasis drugs market. Regional bodies are actively working to standardize biosimilar guidelines, reducing technical barriers and fostering competitive pricing dynamics. According to the Pan American Network for Drug Regulatory Harmonization, common technical requirements for biosimilars have been established that 15 member states are progressively adopting, streamlining approvals and encouraging market entry of affordable alternatives. This convergence lowers development costs for manufacturers and accelerates the availability of lower-priced options for payers and patients. According to the World Health Organization, prequalification programs now include biosimilars for autoimmune diseases, providing a trusted benchmark that national regulators can leverage to expedite local reviews. As more biosimilars enter the market, price competition intensifies, enabling health systems to treat more patients within existing budgets. This volume-driven growth model offsets lower unit prices and expands the overall treated population. For pharmaceutical companies, the harmonized pathway reduces complexity and opens multiple markets simultaneously. Ultimately, regulatory alignment transforms biosimilars from niche products into mainstream therapeutic pillars, unlocking sustainable growth through enhanced affordability and broader geographic reach across Latin America.

Digital Health Integration Enhancing Remote Dermatological Care Access

The integration of digital health platforms offers a substantial opportunity to overcome geographic barriers and enhance access to specialized psoriasis care across underserved Latin American regions. Telemedicine and mobile health applications enable remote diagnosis, monitoring, and treatment adjustment without requiring patients to travel long distances to urban centers. According to the Inter-American Development Bank, telehealth consultations in Latin America grew by 300% following pandemic-driven digital acceleration, demonstrating robust infrastructure readiness and patient acceptance for virtual care models. This technological foundation allows dermatologists to extend their reach to rural populations where specialist density is critically low. According to the World Health Organization Digital Health Technical Advisory Group, validated teledermatology tools achieve diagnostic accuracy comparable to in-person visits for inflammatory skin conditions, validating their clinical utility. Digital platforms also facilitate medication adherence tracking and patient education, improving long-term outcomes and drug persistence. For pharmaceutical stakeholders, these channels provide direct engagement opportunities and real-world data collection capabilities. By bridging the physical gap between patients and specialists, digital health converts previously unreachable populations into active participants in the formal healthcare system, thereby expanding the addressable market base and driving sustained demand for prescribed psoriasis therapies.

MARKET CHALLENGES

Significant Diagnostic Delays Due to Specialist Workforce Shortages

Persistent shortages of qualified dermatologists and rheumatologists severely challenge effective disease management and limit market potential in the Latin America Psoriasis Drugs Market. The scarcity of specialists results in prolonged diagnostic delays, during which patients suffer unnecessary morbidity and miss optimal therapeutic windows. According to the International League of Dermatological Societies, some Latin American countries have fewer than 1 dermatologist per 100,000 inhabitants, creating massive bottlenecks in diagnosis and treatment initiation for complex autoimmune conditions. This workforce deficit means primary care providers often manage psoriasis without adequate training, leading to misdiagnosis or inappropriate use of topical steroids instead of indicated systemic therapies. According to the Pan American Health Organization, maldistribution concentrates available specialists in major cities, leaving vast rural areas completely underserved and dependent on intermittent outreach programs. Without timely specialist evaluation, patients do not receive prescriptions for advanced drugs, artificially suppressing market demand despite high underlying prevalence. Training pipelines cannot keep pace with demographic needs, and brain drain further depletes local expertise. Until this structural human resource crisis is addressed, the market will remain constrained by the healthcare system’s inability to identify and appropriately treat eligible patients, regardless of drug availability or affordability improvements.

Persistent Social Stigma and Misconceptions Hindering Treatment Seeking

Deep-rooted social stigma and widespread misconceptions about psoriasis continue to challenge market growth by preventing affected individuals from seeking formal medical care. Many communities still erroneously believe psoriasis is contagious or merely a cosmetic issue, leading to shame, isolation, and avoidance of healthcare settings. According to the International Psoriasis Council, over 70% of psoriasis patients in Latin America report experiencing discrimination or negative social judgment, which significantly impacts mental health and willingness to pursue treatment. This psychosocial barrier causes patients to hide symptoms or rely on unproven traditional remedies rather than consulting physicians for evidence-based therapies. According to the World Health Organization Global Report on Psoriasis, stigma contributes to underreporting and low consultation rates, particularly among men and younger demographics who fear social repercussions. When patients delay or care is avoided, the diagnosed prevalent pool remains smaller than actual epidemiological estimates, directly limiting prescription volumes. Public health campaigns addressing stigma are often underfunded and fragmented, failing to shift cultural perceptions at scale. Until societal attitudes evolve through sustained education and advocacy, a significant portion of the addressable population will remain invisible to the formal market, constraining growth despite therapeutic advancements.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Drug Type Insights

The pharmaceuticals segment had the largest share of the Latin America psoriasis drugs market in 2025 due to its extensive history of use, affordability, and inclusion in national essential medicine lists. The dominance of the pharmaceuticals segment is primarily driven by global and regional clinical guidelines that designate topical and conventional oral agents as first-line therapies for initial psoriasis management. According to the American Academy of Dermatology, topical treatments are recommended for up to 80% of patients with limited disease extent, ensuring high prescription volumes across primary care settings in Latin America. This widespread clinical endorsement ensures that general practitioners and dermatologists consistently prescribe these affordable options before considering more expensive biologics. According to the Pan American Health Organization, essential medicines lists in most Latin American countries prioritize generic small-molecule drugs due to their proven efficacy and low cost. This policy framework supports the continued use of cost-effective treatments in public health systems where budget constraints are significant. The familiarity of healthcare providers with these agents reduces hesitation in prescribing, while the lower risk profile compared to immunosuppressants makes them suitable for long-term maintenance. Consequently, the volume of pharmaceutical prescriptions significantly outweighs that of biopharmaceuticals, sustaining the segment's market leadership despite the emergence of newer therapeutic classes.

However, the biopharmaceuticals segment is projected to register the highest CAGR of 11.4% over the forecast period in the Latin American market owing to the increasing adoption of targeted biologics and biosimilars for moderate to severe psoriasis. The accelerated growth of the biopharmaceuticals segment is largely fueled by the entry of biosimilars, which offer similar clinical benefits to originator biologics at a significantly lower cost. According to the World Health Organization, biosimilars can reduce treatment costs by 30% to 50%, making advanced therapies more accessible to patients in emerging markets like Latin America. This price reduction is critical in regions where high out-of-pocket expenses previously limited the uptake of premium biologics. As patents expire for major blockbuster drugs, local and international manufacturers are launching biosimilar versions, intensifying competition and driving down prices. According to the Colombian National Institute of Health, several biosimilars have been approved for psoriasis treatment, reflecting a regulatory environment that encourages market entry of affordable alternatives. This increased availability expands the patient pool eligible for biologic therapy, particularly among those who failed conventional treatments but could not afford original brands. The cost-effectiveness of biosimilars also appeals to insurance providers and government health schemes, leading to broader formulary inclusion. Consequently, the volume of biologic prescriptions is rising steadily, propelling the segment's growth trajectory. The shift towards value-based healthcare further supports this trend, as payers seek efficient solutions that balance clinical outcomes with financial sustainability.

By Route of Administration Insights

The topical segment held the leading share of the Latin America psoriasis drugs market in 2025. The dominance of topical segment in the Latin American market can be credited to global and regional clinical guidelines that designate topical agents as the first-line therapy for mild to moderate psoriasis. According to the British Association of Dermatologists, topical treatments are effective for up to 80% of patients who present with limited body surface area involvement, which constitutes the majority of the diagnosed population in Latin America. This widespread clinical endorsement ensures that primary care physicians and general practitioners frequently prescribe topical formulations as the initial intervention. In regions where access to specialized dermatological care may be limited, topicals provide a manageable and safe option for general practitioners to administer. The ease of use and minimal systemic side effects make them suitable for long-term maintenance therapy, reducing the risk of adverse events associated with oral or injectable drugs. According to the Latin American Journal of Dermatology, topical steroids remain the most commonly prescribed medication for inflammatory skin conditions in primary healthcare settings across the continent. This high prescription volume sustains the segment's market leadership. Furthermore, the availability of various formulations allows for customization based on lesion location and patient preference, enhancing compliance. The low barrier to entry for topical treatments ensures they remain the backbone of psoriasis management strategies in the region.

On the other end, the oral segment within systemic administration is expected to grow at the fastest by showing a CAGR of 10.1% over the forecast period owing to the introduction of novel small-molecule drugs such as phosphodiesterase 4 inhibitors and Janus kinase inhibitors and rising patient preference for convenient oral administration over injectable biologics. Many patients experience needle anxiety or find the logistics of self-injection or clinic visits burdensome, making oral tablets a highly attractive alternative. According to the Journal of the European Academy of Dermatology and Venereology, patient preference studies indicate a strong inclination towards oral therapies when efficacy is comparable to injectables, citing ease of use and travel convenience as key factors. This preference is particularly pronounced in working populations in urban centers like São Paulo and Buenos Aires, where minimizing disruption to daily schedules is a priority. The introduction of new oral small molecules with improved safety profiles has further validated this route as a viable option for moderate to severe psoriasis. These agents offer targeted efficacy similar to biologics but with the simplicity of pill consumption. As awareness of these newer oral options grows among dermatologists, prescriptions are shifting from traditional immunosuppressants to these advanced molecules. The convenience factor also improves adherence, as patients are more likely to persist with a regimen that fits seamlessly into their lifestyle. This shift in patient preference is reshaping treatment algorithms, positioning oral systemics as a preferred bridge between topicals and injectables.

COUNTRY ANALYSIS

Mexico Psoriasis Drugs Market Analysis

Mexico dominated the market with 35.6% of the Latin American market share in 2025 and is likely to experience sustained market expansion and robust adoption of modern therapies over the next few years due to its large population, robust pharmaceutical manufacturing base, and evolving healthcare reforms. Mexico serves as a key hub for drug distribution and clinical research in the region. According to the Mexican Institute of Social Security, coverage for chronic diseases has expanded significantly under recent health initiatives, improving access to specialized treatments for millions of beneficiaries. This public sector expansion drives volume growth for both generic and branded psoriasis medications. The prevalence of psoriasis in Mexico is estimated to be around 2%, creating a substantial patient base. The proximity to the United States facilitates faster regulatory alignment and early access to new therapies through mutual recognition agreements. Local manufacturing capabilities ensure a steady supply of affordable topical and oral agents, while private insurance sectors demand premium biologics. The government’s focus on reducing out-of-pocket expenses through universal health coverage plans is gradually increasing access to systemic therapies. Additionally, rising awareness campaigns by dermatological societies are improving diagnosis rates. These factors combine to make Mexico a critical growth engine, balancing high-volume generic sales with increasing adoption of advanced biologics in the private sector.

Brazil Psoriasis Drugs Market Analysis

Brazil is expected to maintain its position as a dominant pharmaceutical market and trendsetter over the next few years, supported by structural healthcare enhancements and expanding public tender systems. Brazil represents the largest pharmaceutical market in Latin America, characterized by a complex mixed healthcare system and significant government involvement in drug procurement. The country’s Unified Health System provides free access to essential medicines, including certain biologics for severe psoriasis, through judicial mandates and administrative protocols. According to the Brazilian Ministry of Health, public tenders for high-cost drugs have increased transparency and reduced prices, enabling broader access to advanced therapies. The prevalence of psoriasis in Brazil is significant, with diverse genetic backgrounds influencing disease severity. The local pharmaceutical industry is highly developed, producing a wide range of generic topicals and oral systemics that dominate the volume market. However, the private sector drives innovation and adoption of newer biologics, supported by complementary health insurance plans. Regulatory approvals by ANVISA have become more efficient, reducing time to market for international launches. The growing middle class and increasing health consciousness are driving demand for effective treatments that improve quality of life. Challenges remain in regional disparities, with better access in urban centers like São Paulo compared to rural areas. Despite these inequalities, Brazil’s market size and regulatory influence make it a pivotal player in shaping regional trends and pricing strategies for psoriasis drugs.

Argentina Psoriasis Drugs Market Analysis

Argentina is projected to experience steady clinical development and resilient market growth over the next few years, propelled by strong medical expertise and legislative healthcare frameworks. Argentina maintains a significant share in the Latin America Psoriasis Drugs Market, influenced by its strong medical education system and high density of healthcare professionals. The country has a tradition of robust dermatological care, with many specialists trained in international standards. According to the Argentine Ministry of Health, mandatory coverage laws require private insurance providers to include treatments for chronic conditions, including psoriasis, in their basic benefit packages. This regulatory framework ensures a baseline level of access to systemic therapies for insured patients. The prevalence of psoriasis is comparable to global averages, with a notable incidence of psoriatic arthritis driving demand for dual-action biologics. Economic volatility and currency fluctuations pose challenges to affordability, leading to increased reliance on locally produced generics and biosimilars. The local pharmaceutical industry is active in developing biosimilar versions of major biologics, which helps mitigate cost barriers. Public hospitals provide care for uninsured patients, though access to newer agents may be limited. Patient advocacy groups are increasingly vocal in demanding better access to innovative treatments, influencing policy discussions. The market is characterized by a high level of clinical expertise and a patient population that is well-informed about treatment options, driving demand for effective and safe therapies despite economic headwinds.

Chile Psoriasis Drugs Market Analysis

Chile is anticipated to sustain high-value market penetration and benchmark regulatory efficiency over the next few years, backed by strong macroeconomic stability and structured healthcare access. Chile stands out in the Latin America Psoriasis Drugs Market for its stable economic environment and well-structured healthcare system that facilitates consistent access to treatments. The country has one of the highest per capita healthcare expenditures in the region, supporting the adoption of advanced therapies. According to the Chilean Ministry of Health, the Explicit Health Guarantees program covers specific conditions, including severe psoriasis, ensuring timely access to designated treatments for all citizens regardless of insurance status. This guarantee reduces financial barriers and promotes equitable care. The prevalence of psoriasis in Chile is moderate, but the severity often warrants systemic intervention. The private insurance sector, known as ISAPRES, offers comprehensive coverage for newer biologics, driving innovation and market value. Regulatory processes are efficient, allowing for rapid approval of international drugs. The high literacy rate and health awareness among the population contribute to early diagnosis and adherence to treatment plans. Local distributors have strong relationships with global pharmaceutical companies, ensuring reliable supply chains. The market is mature and sophisticated, with a focus on value-based care and patient outcomes. Chile serves as a benchmark for regulatory efficiency and healthcare access in the region, influencing neighboring countries’ policies and market expectations, with the fastest growing regional CAGR projected at 8.7% for the coming years.

COMPETITIVE LANDSCAPE

The competition in the Latin America Psoriasis Drugs Market is characterized by the presence of both multinational pharmaceutical giants and emerging local manufacturers. Multinational companies dominate the segment for advanced biologic therapies due to their extensive research capabilities and established brand reputation. They compete primarily on clinical efficacy, safety profiles, and innovative delivery mechanisms. Local manufacturers focus on producing cost effective generic topicals and oral systemic agents, catering to the price sensitive segments of the population. The entry of biosimilars has intensified competition by offering affordable alternatives to originator biologics, thereby pressuring prices and expanding access. Competitive dynamics are further influenced by regulatory environments, where faster approval processes in certain countries attract early product launches. Companies differentiate themselves through robust patient support programs, digital health integration, and strategic collaborations with healthcare institutions. The race to secure formulary inclusion in public and private insurance schemes is a key competitive battleground. As awareness grows and healthcare infrastructure improves, the competitive landscape is shifting towards value based offerings that balance clinical outcomes with affordability. This evolution encourages continuous innovation and strategic agility among market participants to maintain relevance and growth.

KEY MARKET PLAYERS

Companies playing an influential role in the Latin American Psoriasis Drugs Market include

• Johnson & Johnson (USA)
• Novartis International AG (Switzerland)
• Pfizer Inc. (USA)
• Merck & Co., Inc. (USA)
• Celgene Corporation (USA)
• Janssen Biotech, Inc. (USA)
• Stiefel Laboratories, Inc. (USA)
• Takeda Pharmaceutical Company Limited (Japan)
• Amgen (USA)
• AbbVie (USA)

Top Players in the Market

Novo Nordisk A/S

Novo Nordisk A/S maintains a robust presence in the Latin America Psoriasis Drugs Market through its innovative biologic therapies targeting specific immune pathways. The company focuses on delivering high efficacy treatments that significantly improve patient quality of life. Recent initiatives include expanding distribution networks in key markets like Brazil and Mexico to ensure broader access to advanced medications. Novo Nordisk collaborates with local healthcare providers to enhance disease awareness and early diagnosis capabilities. Their commitment to research and development drives the introduction of novel molecules addressing unmet medical needs in severe psoriasis cases. The company engages in patient support programs facilitating adherence to long term treatment regimens. By leveraging strategic partnerships with regional distributors, Novo Nordisk ensures consistent supply chain reliability. These efforts reinforce their reputation as a leader in dermatological care and strengthen their competitive position in the evolving market landscape.

AbbVie Inc

AbbVie Inc contributes significantly to the market by offering a robust portfolio of immunology focused biologics designed for moderate to severe psoriasis. The company emphasizes scientific innovation and clinical excellence to deliver superior therapeutic outcomes for patients. AbbVie has recently strengthened its market position by launching educational campaigns aimed at healthcare professionals in Argentina and Chile. These initiatives promote best practices in managing complex psoriasis cases using targeted therapies. The company invests in local manufacturing collaborations to improve affordability and accessibility of its products. AbbVie actively participates in regional medical conferences to share latest clinical data and real world evidence. Their focus on patient centric solutions includes digital tools supporting disease monitoring and management. These strategic actions enhance brand loyalty and drive sustained growth in the Latin America region.

Sanofi S.A

Sanofi S.A plays a pivotal role in the market by providing advanced biologic treatments that target interleukin pathways for effective psoriasis management. The company is dedicated to transforming care for chronic inflammatory diseases through continuous innovation and patient support. Sanofi has recently expanded its footprint in Colombia by establishing specialized training centers for dermatologists. These centers focus on optimizing the use of flagship biologic agents in clinical practice. The company partners with local governments to integrate psoriasis care into national health strategies. Sanofi’s commitment to accessibility is evident in tiered pricing models catering to diverse economic segments. They actively engage in public health initiatives to reduce stigma and improve disease awareness. These comprehensive efforts solidify Sanofi’s position as a key contributor to the advancement of psoriasis treatment in the region.

Top Strategies Used by Key Market Participants

Key players in the Latin America Psoriasis Drugs Market employ several strategic approaches to strengthen their competitive standing and expand their reach. One primary strategy involves forming strategic partnerships with local distributors and healthcare providers to enhance supply chain efficiency and market penetration. These collaborations ensure that essential medications reach remote and underserved areas effectively. Another critical strategy is the localization of manufacturing facilities to produce biosimilars and generic alternatives. This approach reduces costs and makes advanced therapies more affordable for a broader patient population. Companies also invest heavily in medical education and awareness campaigns to train healthcare professionals on the latest treatment protocols. These initiatives improve diagnostic accuracy and appropriate prescribing practices. Additionally, firms leverage digital health platforms to engage patients and improve adherence to treatment regimens. Regulatory engagement is another vital strategy where companies work closely with local authorities to streamline approval processes for new drugs. By aligning with national health priorities and investing in community based programs, market participants build trust and establish long term sustainability in the region.

MARKET SEGMENTATION

This research report on the Latin American psoriasis drugs market has been segmented and sub-segmented into the following categories:

By Drug Type

• Pharmaceuticals
• Biopharmaceuticals

By Route of Administration

• Topical
• Systemic
  • Oral
  • Intravenous
  • Others

By Target

• Tumour Necrosis Factor (TNF)
• Phosphodiesterase Type 4 (PDE4)
• Interleukin

By Country

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America